{"id":12243,"date":"2023-10-02T17:02:28","date_gmt":"2023-10-02T21:02:28","guid":{"rendered":"https:\/\/ccna-ccnv.ca\/?post_type=ccna_publication&#038;p=12243"},"modified":"2025-03-05T17:02:53","modified_gmt":"2025-03-05T22:02:53","slug":"higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease","status":"publish","type":"ccna_publication","link":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/","title":{"rendered":"Higher angiotensin\u2011converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer&rsquo;s disease"},"content":{"rendered":"<h2>Abstract<\/h2>\n<p>Cognitive decline due to Alzheimer\u2019s disease (AD) is frequent in the geriatric population, which has been disproportionately affected by the COVID-19 pandemic. In this study, we investigated the levels of angiotensin-converting enzyme 2 (ACE2), a regulator of the renin-angiotensin system and the main entry receptor of SARS-CoV-2 in host cells, in\u00a0<i>postmortem<\/i>\u00a0parietal cortex samples from two independent AD cohorts, totalling 142 persons. Higher concentrations of ACE2 protein (p\u2009&lt;\u20090.01) and mRNA (p\u2009&lt;\u20090.01) were found in individuals with a neuropathological diagnosis of AD compared to age-matched healthy control subjects. Brain levels of soluble ACE2 were inversely associated with cognitive scores (p\u2009=\u20090.02) and markers of pericytes (PDGFR\u03b2, p\u2009=\u20090.02 and ANPEP, p\u2009=\u20090.007), but positively correlated with concentrations of soluble amyloid-\u03b2 peptides (A\u03b2) (p\u2009=\u20090.01) and insoluble phospho-tau (S396\/404, p\u2009=\u20090.002). However, no significant differences in ACE2 were observed in the 3xTg-AD mouse model of tau and A\u03b2 neuropathology. Results from immunofluorescence and Western blots showed that ACE2 protein is predominantly localized in microvessels in the mouse brain whereas it is more frequently found in neurons in the human brain. The present data suggest that higher levels of soluble ACE2 in the human brain may contribute to AD, but their role in CNS infection by SARS-CoV-2 remains unclear.<\/p>\n","protected":false},"author":14,"featured_media":0,"template":"","meta":{"_acf_changed":false},"studies-relation":[],"class_list":["post-12243","ccna_publication","type-ccna_publication","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Higher angiotensin\u2011converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer&#039;s disease - CCNA - CCNV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Higher angiotensin\u2011converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer&#039;s disease - CCNA - CCNV\" \/>\n<meta property=\"og:description\" content=\"Abstract Cognitive decline due to Alzheimer\u2019s disease (AD) is frequent ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"CCNA - CCNV\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-05T22:02:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/\",\"name\":\"Higher angiotensin\u2011converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease - CCNA - CCNV\",\"isPartOf\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\"},\"datePublished\":\"2023-10-02T21:02:28+00:00\",\"dateModified\":\"2025-03-05T22:02:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ccna-ccnv.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Higher angiotensin\u2011converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer&#8217;s disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\"},\"alternateName\":\"CCNA - CCNV\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"alternateName\":\"CCNA - CCNV\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"contentUrl\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"width\":696,\"height\":696,\"caption\":\"Canadian Consortium on Neurodegeneration in Aging\"},\"image\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Higher angiotensin\u2011converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease - CCNA - CCNV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/","og_locale":"fr_CA","og_type":"article","og_title":"Higher angiotensin\u2011converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease - CCNA - CCNV","og_description":"Abstract Cognitive decline due to Alzheimer\u2019s disease (AD) is frequent ...","og_url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/","og_site_name":"CCNA - CCNV","article_modified_time":"2025-03-05T22:02:53+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/","url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/","name":"Higher angiotensin\u2011converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease - CCNA - CCNV","isPartOf":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#website"},"datePublished":"2023-10-02T21:02:28+00:00","dateModified":"2025-03-05T22:02:53+00:00","breadcrumb":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/higher-angiotensin%e2%80%91converting-enzyme-2-ace2-levels-in-the-brain-of-individuals-with-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ccna-ccnv.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Higher angiotensin\u2011converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer&#8217;s disease"}]},{"@type":"WebSite","@id":"https:\/\/ccna-ccnv.ca\/fr\/#website","url":"https:\/\/ccna-ccnv.ca\/fr\/","name":"Canadian Consortium on Neurodegeneration in Aging","description":"","publisher":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization"},"alternateName":"CCNA - CCNV","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization","name":"Canadian Consortium on Neurodegeneration in Aging","alternateName":"CCNA - CCNV","url":"https:\/\/ccna-ccnv.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","contentUrl":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","width":696,"height":696,"caption":"Canadian Consortium on Neurodegeneration in Aging"},"image":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication\/12243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication"}],"about":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/types\/ccna_publication"}],"author":[{"embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/users\/14"}],"wp:attachment":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/media?parent=12243"}],"wp:term":[{"taxonomy":"studies-relation","embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/studies-relation?post=12243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}